Mitoxantrone
- Generic Name
- Mitoxantrone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
- Background
An anthracenedione-derived antineoplastic agent.
- Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma
- Associated Therapies
- Autologous hematopoietic stem cell transplant
Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2013-07-24
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 50
- Registration Number
- NCT00842595
- Locations
- 🇫🇷
Hôpital COCHIN, Paris, France
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML
- Conditions
- Interventions
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 32
- Registration Number
- NCT00774046
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2014-03-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 162
- Registration Number
- NCT00770848
Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)
- Conditions
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Goethe University
- Target Recruit Count
- 130
- Registration Number
- NCT00744081
- Locations
- 🇩🇪
University of Frankfurt, Medical Dept. II, Frankfurt, Germany
A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-05-23
- Last Posted Date
- 2014-10-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 138
- Registration Number
- NCT00683475
- Locations
- 🇺🇸
ImClone Investigational Site, Madison, Wisconsin, United States
Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)
- Conditions
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2016-12-09
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 115
- Registration Number
- NCT00661492
- Locations
- 🇺🇸
Paris Regional Cancer Center, Paris, Texas, United States
🇺🇸Melbourne Internal Medicine Associates, Melbourne, Florida, United States
🇺🇸Northern AZ Hematology & Oncology Assoc, Sedona, Arizona, United States
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2016-01-15
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 5
- Registration Number
- NCT00660036
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute / Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell
- Conditions
- Interventions
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 16
- Registration Number
- NCT00656084
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 210
- Registration Number
- NCT00577993
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT00562965
- Locations
- 🇺🇸
Wenatchee Valley Medical Center, Wenatchee, Washington, United States
🇺🇸Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States
🇺🇸Facey Medical Group, Mission Hills, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.